Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified pharmacological treatment versus treatment as usual for bipolar depression after initial treatment failure
2023-506605-19-00Phase 3Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of quetiapine, valproic acid, bupropion, escitalopram, lithium and 2 more in bipolar disorder (BD) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale total score. Planned start Feb 2025; status: authorised.
02
Drugs
quetiapinevalproic acidbupropionescitalopramlithium
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on 2023-506605-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506605-19-00.